In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 imaging is also possible during trastuzumab treatment as the receptor might be saturated. We studied the effect of trastuzumab t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2014-07-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2014.00011 |
| _version_ | 1797288126744363008 |
|---|---|
| author | Sietske B.M. Gaykema Johan R. de Jong Patrick J. Perik Adrienne H. Brouwers Carolien P. Schröder Thijs H. Oude Munnink Alphons H.H. Bongaerts Elisabeth G.E. de Vries Marjolijn N. Lub-de Hooge |
| author_facet | Sietske B.M. Gaykema Johan R. de Jong Patrick J. Perik Adrienne H. Brouwers Carolien P. Schröder Thijs H. Oude Munnink Alphons H.H. Bongaerts Elisabeth G.E. de Vries Marjolijn N. Lub-de Hooge |
| author_sort | Sietske B.M. Gaykema |
| collection | DOAJ |
| description | Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 imaging is also possible during trastuzumab treatment as the receptor might be saturated. We studied the effect of trastuzumab treatment on 111 In-trastuzumab uptake. Patients received trastuzumab weekly and paclitaxel once every 3 weeks. 111 In-trastuzumab was injected on day 1 of cycle 1 and day 15 of cycle 4. Whole-body planar scintigraphy was acquired at different time points postinjection. Tumor uptake and organ distribution between the first and repeated scan series were calculated via residence times. Twenty-five tumor lesions in 12 patients were visualized on both scintigraphy series. Tumor uptake decreased (19.6%; p = .03). The residence times of normal organs remained similar except for the cardiac blood pool (+ 16.3%; p = .014). Trastuzumab treatment decreases tumor 111 In-trastuzumab uptake around 20%. HER2 imaging is feasible during trastuzumab treatment. |
| first_indexed | 2024-03-07T18:44:48Z |
| format | Article |
| id | doaj.art-c7d83cb2c39e4ed4a4830b5d882388fd |
| institution | Directory Open Access Journal |
| issn | 1536-0121 |
| language | English |
| last_indexed | 2024-03-07T18:44:48Z |
| publishDate | 2014-07-01 |
| publisher | SAGE Publications |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj.art-c7d83cb2c39e4ed4a4830b5d882388fd2024-03-02T03:07:10ZengSAGE PublicationsMolecular Imaging1536-01212014-07-011310.2310/7290.2014.0001110.2310_7290.2014.00011In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab TreatmentSietske B.M. GaykemaJohan R. de JongPatrick J. PerikAdrienne H. BrouwersCarolien P. SchröderThijs H. Oude MunninkAlphons H.H. BongaertsElisabeth G.E. de VriesMarjolijn N. Lub-de HoogeHuman epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 imaging is also possible during trastuzumab treatment as the receptor might be saturated. We studied the effect of trastuzumab treatment on 111 In-trastuzumab uptake. Patients received trastuzumab weekly and paclitaxel once every 3 weeks. 111 In-trastuzumab was injected on day 1 of cycle 1 and day 15 of cycle 4. Whole-body planar scintigraphy was acquired at different time points postinjection. Tumor uptake and organ distribution between the first and repeated scan series were calculated via residence times. Twenty-five tumor lesions in 12 patients were visualized on both scintigraphy series. Tumor uptake decreased (19.6%; p = .03). The residence times of normal organs remained similar except for the cardiac blood pool (+ 16.3%; p = .014). Trastuzumab treatment decreases tumor 111 In-trastuzumab uptake around 20%. HER2 imaging is feasible during trastuzumab treatment.https://doi.org/10.2310/7290.2014.00011 |
| spellingShingle | Sietske B.M. Gaykema Johan R. de Jong Patrick J. Perik Adrienne H. Brouwers Carolien P. Schröder Thijs H. Oude Munnink Alphons H.H. Bongaerts Elisabeth G.E. de Vries Marjolijn N. Lub-de Hooge In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment Molecular Imaging |
| title | In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment |
| title_full | In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment |
| title_fullStr | In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment |
| title_full_unstemmed | In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment |
| title_short | In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment |
| title_sort | in trastuzumab scintigraphy in her2 positive metastatic breast cancer patients remains feasible during trastuzumab treatment |
| url | https://doi.org/10.2310/7290.2014.00011 |
| work_keys_str_mv | AT sietskebmgaykema intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment AT johanrdejong intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment AT patrickjperik intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment AT adriennehbrouwers intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment AT carolienpschroder intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment AT thijshoudemunnink intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment AT alphonshhbongaerts intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment AT elisabethgedevries intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment AT marjolijnnlubdehooge intrastuzumabscintigraphyinher2positivemetastaticbreastcancerpatientsremainsfeasibleduringtrastuzumabtreatment |